Lara Sullivan, Pyxis Oncology CEO
Small SPAC to tiny sale: Apexigen sprints to Pyxis Oncology in $16M exit
Pyxis Oncology, the public Boston biotech breathing life into Pfizer’s antibody-drug conjugates platform, will buy Apexigen, a small oncology outfit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
